首页> 美国卫生研究院文献>PLoS Clinical Trials >HIV-1 Disease-Influencing Effects Associated with ZNRD1 HCP5 and HLA-C Alleles Are Attributable Mainly to Either HLA-A10 or HLA-B*57 Alleles
【2h】

HIV-1 Disease-Influencing Effects Associated with ZNRD1 HCP5 and HLA-C Alleles Are Attributable Mainly to Either HLA-A10 or HLA-B*57 Alleles

机译:与ZNRD1HCP5和HLA-C等位基因相关的HIV-1疾病影响效应主要归因于HLA-A10或HLA-B * 57等位基因

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A recent genome-wide association study (GWAS) suggested that polymorphisms in or around the genes HCP5, HLA-C and ZNRD1 confer restriction against HIV-1 viral replication or disease progression. Here, we also find that these alleles are associated with different aspects of HIV disease, albeit mainly in European Americans. Additionally, we offer that because the GWAS cohort was a subset of HIV-positive individuals, selected based in part on having a low viral load, the observed associations for viral load are magnified compared with those we detect in a large well-characterized prospective natural history cohort of HIV-1-infected persons. We also find that because of linkage disequilibrium (LD) patterns, the dominant viral load- and disease-influencing associations for the ZNRD1 or HLA-C and HCP5 alleles are apparent mainly when these alleles are present in HLA-A10- or HLA-B*57-containing haplotypes, respectively. ZNRD1 alleles lacking HLA-A10 did not confer disease protection whereas ZNRD1-A10 haplotypes did. When examined in isolation, the HCP5-G allele associates with a slow disease course and lower viral loads. However, in multivariate models, after partitioning out the protective effects of B*57, the HCP5-G allele associates with disease-acceleration and enhanced viral replication; these associations for HCP5-G are otherwise obscured because of the very strong LD between this allele and a subset of protective B*57 alleles. Furthermore, HCP5 and HLA-C alleles stratify B*57-containing genotypes into those that associate with either striking disease retardation or progressive disease, providing one explanation for the long-standing conundrum of why some HLA-B*57-carrying individuals are long-term non-progressors, whereas others exhibit progressive disease. Collectively, these data generally underscore the strong dependence of genotype-phenotype relationships upon cohort design, phenotype selection, LD patterns and populations studied. They specifically demonstrate that the influence of ZNRD1 alleles on disease progression rates are attributable to HLA-A10, help clarify the relationship between the HCP5, HLA-C and HLA-B*57 alleles, and reaffirm a critical role of HLA-B*57 alleles in HIV disease. Furthermore, as the protective B*57-containing genotypes convey striking salutary effects independent of their strong impact on viral control, it is conceivable that T cell-based therapeutic vaccine strategies aimed at reducing viral loads may be inadequate for limiting AIDS progression, raising the potential need for complementary strategies that target viral load-independent determinants of pathogenesis.
机译:最近的全基因组关联研究(GWAS)表明,基因HCP5,HLA-C和ZNRD1或其周围的多态性赋予了针对HIV-1病毒复制或疾病进展的限制。在这里,我们还发现这些等位基因与HIV疾病的不同方面相关,尽管主要在欧洲美国人中。此外,我们提供的结果是,由于GWAS队列是HIV阳性个体的一个子集,部分是根据病毒载量低而选择的,因此与我们在大型特征明确的前瞻性自然环境中检测到的相关性相比,观察到的病毒载量关联性被放大HIV-1感染者的历史队列。我们还发现,由于连锁不平衡(LD)模式,ZNRD1或HLA-C和HCP5等位基因的主要病毒载量和疾病影响关联很明显,主要是这些等位基因存在于HLA-A10-或HLA-B中*分别包含* 57个单元型。缺乏HLA-A10的ZNRD1等位基因不能赋予疾病保护能力,而ZNRD1-A10的单倍型却不能。单独检查时,HCP5-G等位基因与疾病进程缓慢和病毒载量较低有关。然而,在多变量模型中,在将B * 57的保护作用分开后,HCP5-G等位基因与疾病促进和增强的病毒复制相关。由于此等位基因与保护性B * 57等位基因的子集之间存在非常强的LD,因此这些与HCP5-G的关联会被模糊。此外, HCP5 HLA-C 等位基因将含有 B * 57 的基因型分层为与显着疾病延缓或进行性疾病相关的基因型一种长期存在的难题的解释是为什么某些 HLA-B * 57 携带者是长期非进展者,而另一些则表现出进行性疾病。总的来说,这些数据通常强调了基因型-表型关系对队列设计,表型选择,LD模式和研究人群的强烈依赖性。他们特别证明了 ZNRD1 等位基因对疾病进展速度的影响可归因于 HLA-A10 ,有助于阐明 HCP5 ,< em> HLA-C HLA-B * 57 等位基因,并重申 HLA-B * 57 等位基因在HIV疾病中的关键作用。此外,由于含有保护性 B * 57 的基因型传达了惊人的有益作用,而与它们对病毒控制的强大影响无关,因此可以想到,旨在降低病毒载量的基于T细胞的治疗性疫苗策略可能不够充分为了限制艾滋病的进展,潜在地需要针对以病毒载量无关的发病机制为目标的补充策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号